What is GPS Cancer?
GPS Cancer™ is a test that can identify alterations in the DNA and RNA of a person’s tumor sample, as well as measure the level of specific proteins, to potentially match this information to specific cancer therapies.
Why measure the amounts of specific proteins?
Many cancer therapies target proteins or require proteins to be effective. Knowing how much of a specific protein is present in a tumor can help to better understand how well a cancer therapy will work and can provide physicians with information to develop personalized treatment plans for their patients.
Who is eligible for GPS Cancer?
Patients should discuss with their physician whether GPS Cancer is appropriate for their type of cancer.
How long does it take to receive the GPS Cancer test results?
Results are typically available within three weeks from when the laboratory receives the samples.
How is the GPS Cancer test performed?
The testing of patient samples is done in accredited and certified laboratories according to industry standards. First, the tumor samples are checked by a board-certified pathologist to ensure they are adequate for testing. The samples then undergo three different types of analyses:
1. Whole genome sequencing: pinpoints genomic alterations among the thousands of genes present in an individual tumor cell
2. RNA sequencing: provides information about which of the changes in the genes are important
3. Quantitative proteomics: measures the amounts of specific proteins that are targets for cancer therapies
The tumor alterations are then matche to cancer therapies that might be active against tumors containing the specific alteration or closely related alteration.
How are the GPS Cancer test results interpreted?
A GPS Cancer report listing alterations and potential treatment options, if available, is generated and is sent directly to the physician who ordered the test. The report may list FDA-approved therapies with potential for clinical benefit, as well as cancer therapies to which the cancer may be resistant. The report may also suggest active clinical trials of cancer therapies with potential for clinical benefit.
It should be noted that the report does not recommend a treatment plan, but rather it lists potential options, if any. It is the responsibility of the treating physician to develop a personalized treatment plan after discussing the available treatment options with the patient.